Press releases
-
09/15/2026, Sophia Antipolis, France Median Technologies Secures one of the Largest iCRO Projects in its History
The project was awarded by a leading European pharmaceutical company and long-standing Median customer, whose oncology franchise has become its primary growth driver. The contract has a total value of €8.4 million (approximately $9.5 million).Read more Download 20260915_PR_iCROcontract_EN_final.pdf -
09/10/2026, Sophia Antipolis, France H2 2026 Financial Communication Calendar
Median Technologies to release H1 2026 results on October 29, 2026 after market closeRead more Download 20260910_PR_H22026_calendar_EN.pdf -
09/08/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of August 31, 2026
Disclosure of total number of voting rights and number of shares in the capital as of August 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20260908_PR_shares_votingrights_August2026.pdf -
09/02/2026, Sophia Antipolis, France Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy
Strategic Review to Include Potential Separation of iCRO, Potential U.S. Listing and Other Strategic Alternatives.Read more Download 20260902_PR_SRC_EN_final.pdf -
08/10/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of July 31, 2026
Disclosure of total number of voting rights and number of shares in the capital as of July 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20260810_PR_shares_votingrights_July2026.pdf -
07/30/2026, Sophia Antipolis, France Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening
Following FDA 510(k) clearance and CE marking for eyonis® LCS, Median is now focused on accelerating the product’s commercial adoption in the United States and Europe.Read more Download 20260730_PR_CanonOlea_Median_EN_final-1.pdf -
07/22/2026, Sophia Antipolis, France Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications across the eyonis® Portfolio
Median Technologies today announced its key financial performance for the first half of 2026 and highlighted major regulatory and commercial achievements for eyonis® LCS.Read more Download 20260722_PR_H12026keyfigures_EN.pdf -
07/15/2026, Sophia Antipolis, France Half Year Median Technologies liquidity contract statement – First half of 2026
Median Technologies provides the half year liquidity contract statement for the first half of 2026Read more Download 20260715_PR_LiquiditycontractH12026_EN.pdf -
07/06/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of June 30, 2026
Disclosure of total number of voting rights and number of shares in the capital as of June 30, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20260706_PR_shares_votingrights_June2026-1.pdf -
07/03/2026, Sophia Antipolis, France Median Technologies’ eyonis® LCS Obtains CE Marking
eyonis® LCS has obtained CE marking as a Class IIb medical device, under the new European Medical Device Regulation (MDR 2017/745), enabling commercialization across the European Economic Area.Read more Download 20260703_PR_eyonis_CEMark_EN_final.pdf